Skip to content
20-F

Annual Report (Foreign)

SINOVAC BIOTECH LTD SVA

0001193125-26-194394

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Dec 31, 2024 71.86M sh
Long Term Debt FY 2024 · Dec 31, 2024 $375.76M
Short Term Investments restated FY 2024 · Dec 31, 2023 $9.89B
Short Term Investments restated FY 2024 · Dec 31, 2022 $6.65B
Short Term Investments FY 2024 · Dec 31, 2021 $1.81B
Cash And Equivalents restated FY 2024 · Dec 31, 2023 $1.12B
Cash And Equivalents restated FY 2024 · Dec 31, 2022 $3.88B
Cash And Equivalents FY 2024 · Dec 31, 2021 $11.61B
Stockholders Equity restated FY 2024 · Dec 31, 2023 $8.32B
Stockholders Equity restated FY 2024 · Dec 31, 2022 $8.49B
Stockholders Equity restated FY 2024 · Dec 31, 2021 $9B
Current Liabilities restated FY 2024 · Dec 31, 2023 $1.29B
Current Liabilities restated FY 2024 · Dec 31, 2022 $1.26B
Current Liabilities restated FY 2024 · Dec 31, 2021 $2.52B
Total Liabilities restated FY 2024 · Dec 31, 2023 $1.97B
Total Liabilities restated FY 2024 · Dec 31, 2022 $1.79B
Total Liabilities restated FY 2024 · Dec 31, 2021 $3.21B
Current Assets restated FY 2024 · Dec 31, 2023 $11.6B
Current Assets restated FY 2024 · Dec 31, 2022 $11.3B
Current Assets restated FY 2024 · Dec 31, 2021 $14.94B
Total Assets restated FY 2024 · Dec 31, 2023 $13.61B
Total Assets restated FY 2024 · Dec 31, 2022 $14.03B
Total Assets restated FY 2024 · Dec 31, 2021 $16.76B
Net Income restated FY 2024 · Dec 31, 2023 −$13.49M
Net Income restated FY 2024 · Dec 31, 2022 $14.47M
Net Income restated FY 2024 · Dec 31, 2021 $8.12B
Shares Diluted restated FY 2024 · Dec 31, 2022 71.76M sh
Shares Diluted restated FY 2024 · Dec 31, 2021 71.6M sh
Capex FY 2024 · Dec 31, 2022 $313.86M
Capex restated FY 2024 · Dec 31, 2021 $594.21M
Operating Cash Flow restated FY 2024 · Dec 31, 2022 −$798.12M
Operating Cash Flow restated FY 2024 · Dec 31, 2021 $15.32B
Eps Diluted restated FY 2024 · Dec 31, 2022 $0.20
Eps Diluted restated FY 2024 · Dec 31, 2021 $113.44
Eps Basic restated FY 2024 · Dec 31, 2022 $0.20
Eps Basic restated FY 2024 · Dec 31, 2021 $113.54
Sga Expense restated FY 2024 · Dec 31, 2022 $836.14M
Sga Expense restated FY 2024 · Dec 31, 2021 $602.15M
Rd Expense restated FY 2024 · Dec 31, 2022 $478.69M
Rd Expense restated FY 2024 · Dec 31, 2021 $152.7M
Operating Income restated FY 2024 · Dec 31, 2022 −$508.99M
Operating Income restated FY 2024 · Dec 31, 2021 $17.62B
Gross Profit restated FY 2024 · Dec 31, 2022 $815.24M
Gross Profit restated FY 2024 · Dec 31, 2021 $18.38B
Cost Of Revenue restated FY 2024 · Dec 31, 2022 $658.19M
Cost Of Revenue restated FY 2024 · Dec 31, 2021 $988.92M
Revenue restated FY 2024 · Dec 31, 2022 $1.47B
Revenue restated FY 2024 · Dec 31, 2021 $19.37B